title: Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.
abstract: Levodopa-induced dyskinesias are a common complication of long-term therapy in Parkinson's disease. Although both pre- and post-synaptic mechanisms seem to be implicated in their development, the precise physiopathology of these disabling involuntary movements remains to be fully elucidated. Abnormalities in glutamate transmission (over expression and phosphorylation of N-methyl-D-aspartate receptors) have been associated with the development of levodopa-induced dyskinesias in animal models of Parkinsonism. The role of glutamate function in dyskinetic patients with Parkinson's disease, however, is unclear. We used (11)C-CNS 5161 [N-methyl-3(thyomethylphenyl)cyanamide] positron emission tomography, a marker of activated N-methyl-D-aspartate receptor ion channels, to compare in vivo glutamate function in parkinsonian patients with and without levodopa-induced dyskinesias. Each patient was assessed with positron emission tomography twice, after taking and withdrawal from levodopa. Striatal and cortical tracer uptake was calculated using a region of interest approach. In the 'OFF' state withdrawn from levodopa, dyskinetic and non-dyskinetic patients had similar levels of tracer uptake in basal ganglia and motor cortex. However, when positron emission tomography was performed in the 'ON' condition, dyskinetic patients had higher (11)C-CNS 5161 uptake in caudate, putamen and precentral gyrus compared to the patients without dyskinesias, suggesting that dyskinetic patients may have abnormal glutamatergic transmission in motor areas following levodopa administration. These findings are consistent with the results of animal model studies indicating that increased glutamatergic activity is implicated in the development and maintenance of levodopa-induced dyskinesias. They support the hypothesis that blockade of glutamate transmission may have a place in the management of disabling dyskinesias in Parkinson's disease.
authors.affiliation: Centre for Neuroscience, Imperial College, London, UK.
authors.forename: Imtiaz
authors.initials: I
authors.lastname: Ahmed
authors.forename: Subrata K
authors.initials: SK
authors.lastname: Bose
authors.forename: Nicola
authors.initials: N
authors.lastname: Pavese
authors.forename: Anil
authors.initials: A
authors.lastname: Ramlackhansingh
authors.forename: Federico
authors.initials: F
authors.lastname: Turkheimer
authors.forename: Gary
authors.initials: G
authors.lastname: Hotton
authors.forename: Alexander
authors.initials: A
authors.lastname: Hammers
authors.forename: David J
authors.initials: DJ
authors.lastname: Brooks
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D001931:Brain Mapping; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism*; D011877:Radionuclide Imaging; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa